Inovio's Last Stand: 22 Jobs, $58M, and One Shot at the FDA

Quick explainer: accelerated approval lets the FDA greenlight drugs for serious conditions based on a surrogate endpoint (a stand-in measurement that suggests the drug works) rather than waiting years for definitive proof. It's the express lane. Inovio is arguing that T-cell immune responses and surgery reduction rates are strong enough surrogates to qualify.

The FDA, apparently, isn't so sure.

This doesn't mean the drug is dead. The application is still under review, now classified as a "standard review" rather than accelerated. Inovio has requested a meeting with the FDA to make its case, though as of March 12, that meeting hadn't been scheduled yet.

The distinction matters enormously. Standard review means the FDA will hold INO-3107 to a higher evidence bar, potentially requiring additional clinical data that Inovio may not have the resources to generate.

Running Lean, Running Out of Time

This is where the layoffs fit into the picture. With $58.5 million in cash as of December 31, 2025, Inovio estimates it has enough runway to operate into the fourth quarter of 2026. The company expects to burn around $22 million in the first quarter of 2026 alone.

Do the math, and you'll notice the timing is razor-thin. The FDA's decision date is October 30, 2026. Inovio's cash runs into Q4 2026. The company is essentially threading a needle: it needs to keep the lights on just long enough to get a yes or no from regulators.

That's why every non-essential role got eliminated. Inovio is stripping down to a skeleton crew focused entirely on one thing: getting INO-3107 across the finish line. It's the biotech equivalent of burning your furniture for warmth because the rescue helicopter is supposedly on its way.

The company did trim its full-year net loss from $107.3 million in 2024 to $84.9 million in 2025, and operating expenses dropped from $112.6 million to $86.9 million. Those aren't small reductions. But when your revenue for the year is just $65,343 (yes, thousand), cost-cutting only buys you so much time.

Wall Street Is Oddly Optimistic

Despite all of this, analysts are surprisingly bullish. The stock trades at around $1.73 per share, giving Inovio a market cap of roughly $119 million.

Part of that optimism comes from the math on Inovio's balance sheet. Cash represents more than half the company's market value, which means investors are pricing in almost no value for INO-3107 itself. If the drug gets approved, the stock has massive room to run. If it doesn't, well, there's still some cash to cushion the fall.

But analyst price targets for micro-cap biotechs are a bit like weather forecasts for next month: directionally interesting, rarely precise.

The Bigger Picture for Rare Disease Patients

What makes this story sting is the patient angle. RRP is one of those conditions that's too rare to attract big pharma dollars but devastating enough that people living with it are desperate for options. HPV vaccination programs (like Gardasil) can prevent new cases, but they do nothing for the thousands already diagnosed.

Inovio is, right now, one of the only companies actively pursuing an approved treatment for RRP. If the regulatory path collapses and the cash runs out, those patients go back to square one: an endless cycle of surgeries with no cure in sight.

The next seven months will determine whether Inovio's decade-long bet on DNA medicines pays off or becomes another cautionary tale in biotech. The FDA meeting, whenever it gets scheduled, will be the first real signal. Until then, 112 employees are holding down the fort with $58.5 million and a whole lot of conviction that the science speaks for itself.

Vertex Bet $5 Billion on a Kidney Drug. It Just Paid Off.

Vertex dropped $4.9 billion on a kidney drug most people had never heard of. Two years later, the Phase 3 data just landed, and it's turning heads across the IgA nephropathy space. The stock hit a record high.